Featured Research

from universities, journals, and other organizations

European Union could create incentive for new drug treatments, experts propose

Date:
September 9, 2010
Source:
Duke University
Summary:
Drug companies may be more willing to develop treatments for neglected diseases including malaria, tuberculosis and leishmanaiasis if the European Union would adopt a "priority review voucher" reward system, according to a U.S. business professor and a Spanish policy expert.

Drug companies may be more willing to develop treatments for neglected diseases including malaria, tuberculosis and leishmanaiasis if the European Union would adopt a "priority review voucher" reward system, according to a U.S. business professor and a Spanish policy expert.

Related Articles


The vouchers would give a company accelerated regulatory review of one of its other drugs as a reward for developing a treatment for a neglected disease.

Although these diseases affect more than 1 billion people, they occur most frequently in developing nations, providing little financial incentive for pharmaceutical companies to create and test new treatments.

Writing in the Sept. 11 issue of The Lancet, professor David Ridley of Duke University's Fuqua School of Business and Alfonso Calles-Sánchez, a patent expert with the Spanish Patent Office and former pharmaceutical policy maker at the European Commission, propose a European Union version of the priority review voucher system instituted in the United States in 2007.

The EU voucher would provide priority regulatory review through the European Medicines Agency, as well as accelerated pricing and reimbursement decisions by EU member states.

For example, "If you develop a new drug for malaria, your profitable cholesterol-lowering drug could go on the market a year earlier," global health philanthropist Bill Gates explained at the 2008 World Economic Forum in Davos. "This priority review could be worth hundreds of millions of dollars," Gates said.

The U.S. voucher was originally proposed by Ridley and Duke colleagues Jeff Moe and Henry Grabowski in a 2006 article in the journal Health Affairs. Legislation to create the U.S. priority review voucher system was sponsored by Sens. Sam Brownback and Sherrod Brown and authorized by Congress in 2007.

"By allowing a company to sell its profitable drug sooner, an EU voucher system also would increase the time during which the company could enjoy patent-protected sales," Calles-Sánchez said."The voucher would not, however, delay generics because it would not extend the patent expiration date."

A company that receives approval for a new neglected disease treatment in both the U.S. and EU could receive vouchers in both regions that, combined, could be worth hundreds of millions of dollars in additional sales of a future blockbuster product, the researchers estimate. Vouchers could be sold or transferred between companies, making them valuable as potential revenue sources or assets to make firms more attractive as buyout targets.

"Scientists are aware of molecules that could potentially treat neglected diseases, but they have been mostly unable to make a business case for spending millions of dollars testing those molecules," Ridley said. "A European voucher would provide a strong incentive for organizations to use their knowledge and resources to treat conditions that might otherwise be ignored."

Novartis received the first U.S. priority review voucher in 2009 following FDA approval of Coartem, a treatment for malaria. Several more companies have treatments in late-stage clinical testing that may qualify for vouchers.

"The U.S. voucher and other new incentives have motivated firms to begin clinical testing, but it will take several years for these treatments to reach patients. We expect another voucher to be awarded in the U.S. within the next five years, and after that we could see a new treatment every year," said Ridley. "Given the enormous burden of these diseases, the new treatments could relieve a lot of suffering."

"A European priority review voucher system, combined with the U.S. system, would provide an extraordinarily powerful incentive for companies to invest in treatments for neglected diseases," Calles-Sánchez added.


Story Source:

The above story is based on materials provided by Duke University. Note: Materials may be edited for content and length.


Journal Reference:

  1. David B Ridley, Alfonso Calles Sánchez. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. The Lancet, 2010; 376 (9744): 922-927 DOI: 10.1016/S0140-6736(10)60669-1

Cite This Page:

Duke University. "European Union could create incentive for new drug treatments, experts propose." ScienceDaily. ScienceDaily, 9 September 2010. <www.sciencedaily.com/releases/2010/09/100909193359.htm>.
Duke University. (2010, September 9). European Union could create incentive for new drug treatments, experts propose. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2010/09/100909193359.htm
Duke University. "European Union could create incentive for new drug treatments, experts propose." ScienceDaily. www.sciencedaily.com/releases/2010/09/100909193359.htm (accessed October 31, 2014).

Share This



More Science & Society News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.S. Ebola Response Measures Demonstrated

U.S. Ebola Response Measures Demonstrated

AP (Oct. 31, 2014) — Officials in the Washington area showed off Ebola response measures being taken at Dulles International Airport and the National Institutes of Health. (Oct. 31) Video provided by AP
Powered by NewsLook.com
Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) — NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Killer History on Display at Museum of Death

Killer History on Display at Museum of Death

AP (Oct. 30, 2014) — Visitors take a trip down murderer memory lane at the Museum of Death located in the heart of Hollywood. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) — A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Science & Society

Business & Industry

Education & Learning

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins